Core Points - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [1][3] - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 13-16, 2025, in San Francisco, CA [1][2] - The lead therapeutic candidate of aTyr is efzofitimod, an immunomodulator in clinical development for treating interstitial lung disease [3] Presentation Details - The presentation will take place on January 16, 2025, at 8:15 am PST [2] - Company management will be available for one-on-one meetings with registered investors during the conference [2] - A webcast of the presentation will be available on the company's investor section of the website, with a replay accessible for at least 30 days post-event [2] Company Overview - aTyr leverages evolutionary intelligence to develop therapies targeting fibrosis and inflammation through its tRNA synthetase biology [3] - The company’s discovery platform aims to identify therapeutic intervention points by exploring signaling pathways from its proprietary library of tRNA synthetase domains [3] - Interstitial lung disease, the focus of aTyr's lead candidate, is characterized by immune-mediated disorders leading to lung inflammation and progressive fibrosis [3]
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference